In collaboration with Verily Life Sciences (formerly Google Life Sciences), Alcon developed EyeScreen™ as a non-invasive screening tool for diabetic retinopathy – a leading cause of blindness worldwide among diabetic patients. The initiative aims to improve early detection rates by making this technology accessible in primary care settings.